These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis. Thiery-Vuillemin A; Montange D; Kalbacher E; Maurina T; Nguyen T; Royer B; Bouchet S; Bazan F; Curtit E; Pivot X Ann Oncol; 2011 Sep; 22(9):2152-2154. PubMed ID: 21878429 [No Abstract] [Full Text] [Related]
23. High-intensity focused ultrasound combined with herpes simplex virus thymidine kinase gene-loaded ultrasound-targeted microbubbles improved the survival of rabbits with VX₂ liver tumor. Zhou SJ; Li SW; Wang JJ; Liu ZJ; Yin GB; Gong JP; Liu CA J Gene Med; 2012; 14(9-10):570-9. PubMed ID: 22941868 [TBL] [Abstract][Full Text] [Related]
24. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888 [TBL] [Abstract][Full Text] [Related]
26. Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma. Zhao Q; Guo J; Wang G; Chu Y; Hu X Oncotarget; 2017 Jan; 8(1):1668-1677. PubMed ID: 27926489 [TBL] [Abstract][Full Text] [Related]
28. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. Tsimafeyeu I; Zart JS; Chung B BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142 [TBL] [Abstract][Full Text] [Related]
29. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522 [TBL] [Abstract][Full Text] [Related]
30. Near-infrared light-activated IR780-loaded liposomes for anti-tumor angiogenesis and Photothermal therapy. Yang X; Li H; Qian C; Guo Y; Li C; Gao F; Yang Y; Wang K; Oupicky D; Sun M Nanomedicine; 2018 Oct; 14(7):2283-2294. PubMed ID: 29981460 [TBL] [Abstract][Full Text] [Related]
31. High-intensity focused ultrasound-induced, localized mild hyperthermia to enhance anti-cancer efficacy of systemic doxorubicin: an experimental study. Chae SY; Kim YS; Park MJ; Yang J; Park H; Namgung MS; Rhim H; Lim HK Ultrasound Med Biol; 2014 Jul; 40(7):1554-63. PubMed ID: 24642222 [TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of cationic hybrid liposomes on the growth of human renal cell carcinoma. Umebayashi M; Makizono T; Ichihara H; Matsumoto Y; Ueoka R Anticancer Res; 2010 Feb; 30(2):327-37. PubMed ID: 20332436 [TBL] [Abstract][Full Text] [Related]
34. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Canter D; Kutikov A; Golovine K; Makhov P; Simhan J; Uzzo RG; Kolenko VM Can J Urol; 2011 Aug; 18(4):5819-25. PubMed ID: 21854714 [TBL] [Abstract][Full Text] [Related]
35. A Novel Microbubble Capable of Ultrasound-Triggered Release of Drug-Loaded Nanoparticles. Wang J; Li P; Tian R; Hu W; Zhang Y; Yuan P; Tang Y; Jia Y; Zhang L J Biomed Nanotechnol; 2016 Mar; 12(3):516-24. PubMed ID: 27280249 [TBL] [Abstract][Full Text] [Related]
37. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119 [TBL] [Abstract][Full Text] [Related]
38. CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation. Liu B; Diaz Arguello OA; Chen D; Chen S; Saber A; Haisma HJ PLoS One; 2020; 15(5):e0232985. PubMed ID: 32413049 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Zucchetti M; Bonezzi K; Frapolli R; Sala F; Borsotti P; Zangarini M; Cvitkovic E; Noel K; Ubezio P; Giavazzi R; D'Incalci M; Taraboletti G Cancer Chemother Pharmacol; 2013 Oct; 72(4):879-87. PubMed ID: 23978989 [TBL] [Abstract][Full Text] [Related]
40. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. von Roemeling CA; Marlow LA; Wei JJ; Cooper SJ; Caulfield TR; Wu K; Tan WW; Tun HW; Copland JA Clin Cancer Res; 2013 May; 19(9):2368-80. PubMed ID: 23633458 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]